# Top 50 Health Care Startup Investors in Denmark in June 2026 ## Novo Holdings - Type: VC Fund - Location: Hellerup, Hovedstaden, Denmark - Relevant deals: 32 - Stages: Series A, Series B, Series C - Focus: Biotechnology, Health Care, Medical Novo Holdings is a world-leading life science investor with a focus on creating long-term value. ## Vaekstfonden - Type: VC Fund - Location: Hellerup, Hovedstaden, Denmark - Relevant deals: 18 - Stages: Seed, Pre-Seed - Focus: Software, Information Technology, SaaS Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering. ## BioInnovation Institute - Type: VC Fund - Location: Copenhagen, Hovedstaden, Denmark - Relevant deals: 18 - Stages: Convertible Note, Pre-Seed, Debt Financing - Focus: Biotechnology, Medical, Health Care BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark. ## Export and Investment Fund - Type: VC Fund - Location: Hellerup, Hovedstaden, Denmark - Relevant deals: 15 - Stages: Seed, Series A - Focus: Software, Biotechnology, Health Care Denmark's Export and Investment Fund (EIFO) serves as a single point of contact for Danish firms seeking risk-tolerant government finance. We aspire to help successful enterprises that can expand the Danish economy and green the world on a daily basis, guided by professionalism and an international perspective. ## PSV - Type: VC Fund - Location: Lyngby, Hovedstaden, Denmark - Relevant deals: 15 - Stages: Seed, Pre-Seed - Focus: Software, Information Technology, SaaS PSV cares about a conscious future. As a venture house, our mission is to clear the path for founders who build companies that matter. Our hybrid setup, comprising PSV Foundry, PSV Lab, and two unique venture funds, PSV Tech and PSV Hafnium, sets us free from adhering to a singular method. Rather we rethink existing ways and models to maximise our impact beyond any individual firm or investment. Together, we can punch above our weight. ## Seed Capital - Type: VC Fund - Location: Copenhagen, Hovedstaden, Denmark - Relevant deals: 13 - Stages: Seed, Series A - Focus: Software, Health Care, SaaS Seed Capital invests in Danish tech businesses with global ambitions. We are focused on "late seed"-stage companies, typically investing 1-3 MEUR in rounds of 1-6 MEUR. Proud backers of Trustpilot, Vivino, Lunar, Templafy, Dixa, Forecast, and many other great companies. ## Sunstone Life Science Ventures - Type: VC Fund - Location: Copenhagen, Hovedstaden, Denmark - Relevant deals: 7 - Stages: Series B, Series A - Focus: Biotechnology, Health Care, Medical Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations. ## People Ventures - Type: VC Fund - Location: Taastrup, Hovedstaden, Denmark - Relevant deals: 7 - Stages: Seed, Pre-Seed, Series A - Focus: Software, Health Care, Internet of Things Backing founders with people, money and presence | People Ventures ## West Hill Capital - Type: VC Fund - Location: London, England, United Kingdom - Relevant deals: 6 - Stages: Series A, Seed - Focus: Software, Health Care, Financial Services West Hill Corporate Finance is a leading private equity venture capital firm providing EIS qualifying high-growth investments to private individuals. ## Oskare Capital - Type: VC Fund - Location: Paris, Ile-de-France, France - Relevant deals: 6 - Stages: Seed, Series A, Pre-Seed - Focus: Health Care, Biotechnology, Medical Oskare Capital is a venture capital firm. ## Gilde Healthcare - Type: VC Fund - Location: Utrecht, Utrecht, The Netherlands - Relevant deals: 5 - Stages: Series B, Series C, Series A - Focus: Biotechnology, Health Care, Medical Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company. ## Jesper Brok - Type: Angel - Location: Copenhagen, Hovedstaden, Denmark - Relevant deals: 4 - Stages: Pre-Seed, Seed, Angel - Focus: E-Learning, Recruiting, Communities Jesper Brok is the Founder of Tjommi and Legalfinder.com. ## Innovestor - Type: VC Fund - Location: Helsinki, Southern Finland, Finland - Relevant deals: 4 - Stages: Seed, Pre-Seed - Focus: Software, Health Care, Information Technology Innovestor is an active Finnish investment manager, focusing on venture capital, real estate, and energy storage. We also offer corporate venturing services. ## HealthCap - Type: VC Fund - Location: Stockholm, Stockholms Lan, Sweden - Relevant deals: 4 - Stages: Series B, Series A - Focus: Biotechnology, Health Care, Medical HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society. ## RA Capital Management - Type: VC Fund - Location: Boston, Massachusetts, United States - Relevant deals: 4 - Stages: Series B, Series C, Post-IPO Equity - Focus: Biotechnology, Health Care, Therapeutics RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products. ## VF Venture - Type: VC Fund - Relevant deals: 4 - Stages: Seed, Series A - Focus: Software, SaaS, Biotechnology Vaekstfonden makes equity investments in Danish companies with a track record as well as in young entrepreneurial, innovative enterprises with an ambition for global growth. ## Innovation Fund Denmark - Type: VC Fund - Location: Copenhagen, Hovedstaden, Denmark - Relevant deals: 4 - Stages: Grant, Pre-Seed, Seed - Focus: Software, Biotechnology, SaaS Innovation Fund Denmark invests in the development of new knowledge and technology creating growth and employment in Denmark. The Fund focuses on societal challenges, strengthens research, and increases innovation commitment within private companies.The Fund provides risk capital that enables cutting-edge initiatives to achieve resultssubstantially impacting the Danish society. Innovation Fund Denmark is also responsible for the future societal partnerships, where companies, universities, and public authorities will work together on challenges facing the society today. ## Delphinus Venture Capital - Type: VC Fund - Relevant deals: 4 - Stages: Seed, Pre-Seed, Series A - Focus: Health Care, Food and Beverage, Hospital Delphinus Venture Capital is a venture investment management firm. ## DSM Venturing - Type: VC Fund - Location: Heerlen, Limburg, The Netherlands - Relevant deals: 3 - Stages: Series A, Series B - Focus: Biotechnology, Health Care, Manufacturing Innovators in nutrition, health, and beauty. Together, we bring progress to life by combining the essential, the desirable, and the sustainable. ## Sofinnova Partners - Type: VC Fund - Location: Paris, Ile-de-France, France - Relevant deals: 3 - Stages: Series A, Series B, Series C - Focus: Biotechnology, Health Care, Medical Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. ## Ugly Duckling Ventures - Type: VC Fund - Location: Copenhagen, Hovedstaden, Denmark - Relevant deals: 3 - Stages: Pre-Seed, Seed - Focus: Software, Information Technology, Artificial Intelligence At Ugly Duckling Ventures, we make capital, know-how, and real-world application available to Nordic ventures at the seed & pre-seed stage. We are operational by nature and want to get in the grind as we excel at getting early-stage ventures ready for scale. ## Ysios Capital - Type: VC Fund - Location: San Sebastian, Pais Vasco, Spain - Relevant deals: 3 - Stages: Series A, Series B, Series C - Focus: Biotechnology, Health Care, Medical Leading #lifesciences #venturecapital firm financing highly #innovative #biotechnology companies #worlwide. ## Stine Molgaard Sorensen - Type: Angel - Location: Copenhagen, Hovedstaden, Denmark - Relevant deals: 3 - Stages: Pre-Seed, Seed - Focus: Robotics, Software, Health Care Stine Molgaard Sorensen is the Co-founder and COO of Radiobotics. ## Antler - Type: VC Fund - Location: Singapore, Central Region, Singapore - Relevant deals: 3 - Stages: Pre-Seed, Seed, Series A - Focus: Software, Artificial Intelligence, Information Technology Build your next company with Antler, a global day zero investor enabling exceptional founders to start great companies, from the very beginning. Apply now! ## Bioqube Ventures - Type: VC Fund - Location: Hasselt, Limburg, Belgium - Relevant deals: 3 - Stages: Seed, Series A, Series B - Focus: Biotechnology, Therapeutics, Life Science Bioqube Ventures is a specialist life sciences venture capital fund investing in European biotech companies developing innovative therapeutic assets and technologies. We put our venture creation experience at work to translate and de-risk scientific innovation, advancing our investment portfolio and maximising value for investors.Bioqube Venturesinvests through its independent fund “Bioqube Factory Fund I”: … an early stage venture capital fund – dedicated to advancing exciting science in vibrant European ecosystems to breakthrough therapies for patients.… a fit-for-purpose dual investment model – besides more classical investments in first investment rounds, we will have special attention for so called “Create” projects that require additional de-risking prior to creating new ventures. … a hands-on approach – the team is a mix of fund managers, sector experts and serial entrepreneurs that have a proven track record in successfully leading companies on their growth paths.Medtech, healthtech and diagnostics are not part of our current investment scope. ## byFounders - Type: VC Fund - Location: Copenhagen, Hovedstaden, Denmark - Relevant deals: 3 - Stages: Seed, Pre-Seed, Series A - Focus: Software, Artificial Intelligence, Health Care byFounders is the community-powered early-stage venture fund investing in globally ambitious teams connected to the Nordic and Baltic countries. With its unique Collective of founders and operators, byFounders offers its portfolio operational expertise and a global network. Believing in the power of tech to shape our future, byFounders takes an impact-aware approach to investing and working with the broader startup ecosystem. ## Forbion Capital Partners - Type: VC Fund - Location: Naarden, Noord-Holland, The Netherlands - Relevant deals: 3 - Stages: Series B, Series A, Series C - Focus: Biotechnology, Health Care, Medical Impacting the future of medicine. ## Crowberry Capital - Type: VC Fund - Location: Reykjavík, Gullbringusysla, Iceland - Relevant deals: 3 - Stages: Seed, Series A, Pre-Seed - Focus: Software, Gaming, Health Care Crowberry Capital invests at seed and early stage in emerging technology ventures in the Nordics. Our mission is to back people that are good for companies and build companies that are good for people. We have a strong follow-through philosophy and commit to putting your company first. ## EIR Ventures - Type: VC Fund - Location: Stockholm, Stockholms Lan, Sweden - Relevant deals: 3 - Stages: Series A, Seed - Focus: Biotechnology, Health Care, Therapeutics EIR Ventures is a new Life Science Venture Group in the Nordics. ## Sweet Capital - Type: VC Fund - Location: Stockholm, Stockholms Lan, Sweden - Relevant deals: 3 - Stages: Seed, Series A - Focus: Apps, Software, Mobile Sweet Capital is the private investment fund of the founders of King.com (Candy Crush Saga), following their $5.9b sale to Activision Blizzard in 2015 (ATVI:US; acq. MSFT:US). ## Crista Galli Ventures - Type: VC Fund - Location: Copenhagen, Hovedstaden, Denmark - Relevant deals: 3 - Stages: Seed, Pre-Seed, Series A - Focus: Health Care, Medical, Wellness Physician-led venture capital investing in TechBio, DeepTech Healthcare, and Digital Health. ## Wellcome Trust - Type: VC Fund - Location: London, England, United Kingdom - Relevant deals: 2 - Stages: Grant, Series C - Focus: Biotechnology, Health Care, Medical Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England. ## Inventure - Type: VC Fund - Location: Helsinki, Southern Finland, Finland - Relevant deals: 2 - Stages: Seed, Series A, Series B - Focus: Software, Information Technology, Health Care Since 2005, Inventure has backed over 90 companies including Wolt, Swappie, Jobbatical, aiMotive, and more. ## Lundbeckfonden Ventures - Type: VC Fund - Location: Copenhagen, Hovedstaden, Denmark - Relevant deals: 2 - Stages: Series B, Series A, Series C - Focus: Biotechnology, Health Care, Therapeutics Lundbeckfond Ventures is an evergreen life science venture fund established in the autumn of 2009 and wholly owned by the Lundbeck Foundation. The structure as an evergreen fund allows flexibility in the investment approach and the possibility, when appropriate, to take a long-term perspective in the investments. On an annual basis, LundbeckfondVentures invests up to € 50 million.Lundbeckfond Ventures is a financially driven venture fund generating returns to support the group's activities and operating independently from the Lundbeck Foundation’s controlling ownerships in H. Lundbeck A/S, ALK-Abelló and Falck. ## Balderton Capital - Type: VC Fund - Location: London, England, United Kingdom - Relevant deals: 2 - Stages: Series A, Series B, Series C - Focus: Software, Financial Services, Artificial Intelligence In the two decades since our founding, we have worked with hundreds of extraordinary European founders, and have raised eight funds totalling more than $3bn. ## CAPNOVA - Type: VC Fund - Location: Aarhus, Midtjylland, Denmark - Relevant deals: 2 - Stages: Seed, Pre-Seed - Focus: Software, Information Technology, B2B They are an investment and development company providing capital, solid business experience and a strong network in order to turn innovative ideas into successful businesses. They cover all of Denmark from their offices in Aarhus, Roskilde, Copenhagen, Viborg and Kalundborg. ## NOON Ventures - Type: VC Fund - Location: Copenhagen, Hovedstaden, Denmark - Relevant deals: 2 - Stages: Seed, Series A - Focus: Biotechnology, AgTech, Farming Noon Ventures is a Copenhagen-based, early-stage venture investor established in 2020. We invest in proven transformative technologies with the potential to impact environmental or climate challenges. ## Bruce Linton - Type: Angel - Location: Ottawa, Ontario, Canada - Relevant deals: 2 - Stages: Post-IPO Equity, Seed, Pre-Seed - Focus: Cannabis, Health Care, Biotechnology Mr. Linton is the founder of Canopy Growth Corporation (CGC) and co-founder of Tweed Marijuana Inc.Bruce’s primary focus has been to position cannabis brands in a competitive market and to raise the capital necessary to fund such operations. Bruce’s experience as a founder, CEO, and Board member across a wide variety of enterprises has influencedthe positive start of Canopy Growth, which to date has enjoyed market support for capital raises of over $150 million and the distinction of being the first company in the industry to be offered debt instruments by a federal lender. Bruce has led three M&A transactions valued over $500 million total since founding CGC. In addition to his leadership responsibility at Canopy Growth, Bruce is the CEO of communications company Martello Technologies. After beginning his career at Newbridge Networks Corporation, he has since held positions that include General Manager and Re-Founder of Computerland.ca, President and Co-Founder of webHancer Corp, and part of the establishing team at CrossKeys Systems Corporation. He was also part of the leadership team for the NASDAQ/TSX initial public offering at CrossKeys. Bruce has been responsible for the acquisition and/or disposition of over $600 million in business assets, and has established regular engagement with the World Bank and Asia Development Bank while focused on markets in India, Philippines, China, Peru, Colombia, Ecuador, Azerbaijan and Uzbekistan. He is the past Chairman of the Ottawa Community Loan Foundation, past Board Member and Treasurer of Canada World Youth past Board of Governor for Carleton University, past President of the Nepean Skating Club and past President of the Carleton University Students Association. ## Acorn Venture Fund - Type: VC Fund - Relevant deals: 2 - Stages: Seed - Focus: Health Care Venture Capital ## Lars Fjeldsoe-Nielsen - Type: Angel - Location: London, England, United Kingdom - Relevant deals: 2 - Stages: Seed, Series A, Series B - Focus: Software, Information Technology, Mobile Apps Lars Fjeldsoe-Nielsen grew up across Africa, from Angola and Guinea-Bissau to Tanzania and Libya, after his family fled the Angolan Civil War as refugees. Those early experiences instilled in him a belief that education, technology, and social innovation can transform lives and continue to anchor his career and philanthropic activities to this day.Today, Lars is a General Partner at Owl Ventures ($2.2 billion AUM), the world’s leading venture capital firm focused exclusively on education technology. He leads Owl’s expansion across Europe, Africa, and global markets, backing founders who harness AI and breakthrough technologies to make learning more accessible and impactful.Before joining Owl, Lars co-founded 2xN, an early-stage fund at the frontier of deeptech and quantum innovation, with standout investments including Quantinuum (valued above $10 billion), Oxford Ionics (acquired by IonQ in a $1 billion deal), QSimulate, and Sparrow Quantum. Prior to that, he was a General Partner at Balderton Capital in London during which time the firm led the Seed and Series A rounds in Revolut. His investments also span education (Labster, uLesson, StudySmarter, Kukua), mobility (Yassir, Voi, Monta, NoTraffic), and mobile and frontier tech (Hiya, Monarch Money, Rahko, Pocket, Colossal, Celus, Octant Bio, Vivino, OpenSea, Blue Bottle Coffee).Lars previously spent a decade in Silicon Valley, shaping some of tech’s most iconic growth stories. At Uber, he joined when it operated in fewer than 20 cities and, as Vice President, forged global alliances with Verizon and América Móvil that fueled its international expansion. Before Uber, as Head of Mobile at Dropbox, he was among the first 25 employees and helped the company reach its first 100 million users through partnerships with Samsung and other OEMs.Despite his career in technology and venture capital, Africa has never left Lars’s journey. After his father’s passing, he returned to Angola to trace his family’s history, discovering that his sister had died of malaria as a child. That revelation transformed a personal loss into a mission. A technologist turned humanitarian innovator, Lars filed a patent for genetically modified mosquitoes that light up when carrying malaria and began funding malaria-research projects in Angola through partnerships with global nonprofits. In 2024, he climbed Mount Kilimanjaro to raise funds for malaria research, following earlier campaigns such as climbing the Matterhorn and crossing the Sahara by motorbike.A Danish-Portuguese national who served with the Royal Danish Guards, Lars holds an MBA from London Business School, where he was a member of the Board of Governors and Chairman of the Endowment Fund, an MSc from Oxford University (Keble College), and a BSc from King’s College London. Across every chapter, from refugee to technologist to investor, his purpose endures: advancing education, health, and innovation as catalysts for social change. ## CBC Investment Group - Type: VC Fund - Location: Gothenburg, Vastra Gotaland, Sweden - Relevant deals: 2 - Stages: Seed, Series B - Focus: Software, Biotechnology, SaaS CBC Investment Group started in 2009 in the midst of the financial crisis. The banks were on their knees, start-ups of small and medium-sized companies - all of a sudden they saw their credit and credit promises turned into demands for quick repayment and empty words. Serious talented entrepreneurs' ideas and companies risked going completelyunnecessary. In response to this crisis, they started the CBC Investment Group. ## Christian Dörffer - Type: Angel - Location: Lisbon, Lisboa, Portugal - Relevant deals: 2 - Stages: Seed, Series A, Pre-Seed - Focus: Software, Apps, Mobile Christian Dorffer is based out of Copenhagen, Capital Region of Denmark and is the Managing Partner and Founder of Florent Venture Partners. Christian previously worked at Defiance Capital as a Founder. Christian Dorffer attended Copenhagen Business School. ## Thomas Ryge Mikkelsen - Type: Angel - Location: Copenhagen, Hovedstaden, Denmark - Relevant deals: 2 - Stages: Seed, Series A - Focus: E-Commerce, Beauty, Fashion Thomas Ryge Mikkelsen is an Investor and Chairman at Nøie. ## Novo Ventures - Type: VC Fund - Location: Bagsværd, Hovedstaden, Denmark - Relevant deals: 2 - Stages: Series B, Series A, Series C - Focus: Biotechnology, Health Care, Medical Novo Holdings is a world-leading life science investor with a focus on creating long-term value. ## Alexander Rindom-Andersen - Type: Angel - Relevant deals: 2 - Stages: Pre-Seed - Focus: Mobile, Software, Freelance Alexander Rindom-Andersen is the Co-founder & CEO @ Naetion ## VentureFriends - Type: VC Fund - Location: Athens, Attiki, Greece - Relevant deals: 2 - Stages: Seed, Series A, Pre-Seed - Focus: FinTech, E-Commerce, Software Backing ambitious early-stage founders across Europe and MENA ## Karolinska - Type: VC Fund - Location: Solna, Stockholms Lan, Sweden - Relevant deals: 2 - Stages: Seed, Series A - Focus: Biotechnology, Health Care, Pharmaceutical Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatestreturn on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.Karolinska Development has developed a well-structured selection process to identify the most commercially attractive medical innovations screened by KIAB. Pharmaceutical development is a high-risk enterprise. In most cases, development projects fail because of side effects or insufficient efficacy. Successful selection of innovations is fundamental to Karolinska Development’s business model, which makes the inflow of new projects crucial. One key to success lies in selecting those innovations that can be developed from scientific findings to products and have significant commercial potential. To date, over 1,300 projects have been screened by KIAB.The portfolio companies are often founded together with the innovators and are initially operated as virtual companies with few or no employees. During the first six to twelve months, the companies normally have minimal fixed costs and technological development is outsourced.The innovator, who is often employed at an academic institution, normally participates as a board member and scientific advisor. The CEO of a portfolio company cooperates closely with a representative of Karolinska Development, who in most cases is also a board member of the company. The companies are capitalized to reach their next milestone, usually within a period of six to eighteen months. Development projects are continuously monitored, and those that do not meet their stipulated targets are discontinued. In the first three to four years, a portfolio company’s operating expenses are often limited to a few million Swedish kronor per year, which cover the cost of external studies and the salary of the staff. In subsequent years, Karolinska Development and other investors play an important role recruiting key expertise to the companiesKarolinska Development intends to realize value by exiting portfolio companies or through out-licensing of projects. Such transactions (especially out-licensing) are often structured as single upfront payments followed by payments based on predetermined milestones and royalties on sales. Although Karolinska Development has a flexible exit strategy, pharmaceutical products are, for two reasons, preferably exited at Phase II. First a successful Phase II study indicates that the pharmaceutical has an effect on patients, which is an important value-enhancing factor when negotiating out-licensing or sales. Secondly, finalizing product development and undertaking Phase III clinical trials frequently requires very large patient populations. In many cases this requires much greater resources than those available at Karolinska Development but these can be found in established pharmaceutical companies. Several licensing deals were closed in 2011 involving projects with a similar focus and development phase to Karolinska Development's projects. ## SOSV - Type: VC Fund - Location: Princeton, New Jersey, United States - Relevant deals: 2 - Stages: Seed, Convertible Note, Pre-Seed - Focus: Biotechnology, Health Care, Software SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment. ## Industrifonden - Type: VC Fund - Location: Stockholm, Stockholms Lan, Sweden - Relevant deals: 2 - Stages: Series A, Seed - Focus: Software, Biotechnology, Information Technology Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA. ## Sagitta Ventures - Type: VC Fund - Location: Copenhagen, Hovedstaden, Denmark - Relevant deals: 2 - Stages: Series B - Focus: Aerospace Sagitta Ventures invests in early-stage companies in the Nordics and provides long-term capital backing for well-managed businesses that are seeking minority investors without a defined exit horizon.